주요 내용으로 건너 뛰기

Resmetirom: A pioneering NASH clinical program

Nonalcoholic fatty liver disease (NAFLD) is a condition wherein the liver stores excess fat. Nonalcoholic steatohepatitis (NASH) is one type of NAFLD. Individuals with obesity and type 2 diabetes appear to be at greater risk of developing NAFLD. In recent years, NASH and NAFLD have been renamed MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated … Continued

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

An novel single dose regimen of tremelimumab combined with durvalumab could be a way to treat unresectable hepatocellular carcinoma. In this recently published Clinical Cancer Research study, co-authored by Certara’s Rajesh Krishna, the findings reveal that overall survival was longer for patients given this drug regimen.

Key Considerations to Ensure Maximal Probability of Antibody Drug Conjugate Development Success

Antibody drug conjugates (ADC) are a unique way to obliterate tumor cells and represent an underutilized immunotherapeutics option in oncology, whether as monotherapy or in combinations. The first FDA approval of an ADC was in 2011, with the introduction of brentuximab vedotin (trademarked Adcetris) by Seattle Genetics (1). ADC development is inherently challenging because it … Continued

1 of 1
Powered by Translations.com GlobalLink Web Software